Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-11
2006-07-11
Nashed, Nashaat T. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S402000, C530S345000, C530S350000
Reexamination Certificate
active
07074755
ABSTRACT:
The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein EPO is covalently conjugated to a non-antigenic hydrophilic polymer covalently linked to an organic molecule that increases the circulating serum half-life of the composition. The invention thus relates to EPO derivatives described by the formula EPO-(X-Y)Nwhere EPO is erythropoietin or its pharmaceutical acceptable derivatives having biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells, X is PEG or other water soluble polymers, Y is an organic molecule that increases the circulating half-life of the construct more than the PEG alone and N is an integer from 1 to 15. Other molecules may be included between EPO and X and between X and Y to provide the proper functionality for coupling or valency.
REFERENCES:
patent: 5438040 (1995-08-01), Ekwuribe
patent: 6025324 (2000-02-01), Bailon et al.
patent: 6077939 (2000-06-01), Wei et al.
patent: 6180134 (2001-01-01), Zalipsky et al.
patent: 6340742 (2002-01-01), Burg et al.
patent: 6465694 (2002-10-01), Baudys et al.
patent: 0 539 167 (1992-10-01), None
patent: 0 605 963 (1993-12-01), None
patent: WO 94/28024 (1994-12-01), None
patent: WO 00/26256 (2000-05-01), None
patent: WO 01/02017 (2001-01-01), None
Zalipsky et al. Peptide Attachment to Extremities of Liposomal Surface Grafted PEG Chains: Preparatoin of the Long-Circulating Form of Laminin Pentapeptide, YIGSR. 1995, Bioconjugate Chem. 6: 705-708.
Allen et al. A new Strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. 1995, Biochim. Biophys. Acta 1237: 99-108.
McKenzie, Shrirlyn B. Textbook of Hematology, 1996, William & Wilkins, Baltimore, MD, p. 40.
Centocor, Inc.
Dow Kenneth J.
Nashed Nashaat T.
Schnizer Holly
LandOfFree
Erythropoietin conjugate compounds with extended half-lives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Erythropoietin conjugate compounds with extended half-lives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietin conjugate compounds with extended half-lives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3595350